ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Drug Delivery Technologies for the Treatment of Age-Related Macular Degeneration.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Nanocarrier-Mediated Non-Invasive Drug Delivery for Wet Age-Related Macular Degeneration: Advances and Translational Challenges.Pharmaceutics · 2026Review
- Redox- and Photo-Responsive FeACS applied materials & interfaces · 2026Article
- The role of NLRP3 inflammasome in age-related macular degeneration: mechanisms and therapeutic prospects.Frontiers in aging neuroscience · 2026Review
- Drug Delivery Technologies for the Treatment of Age-Related Macular Degeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Age-related macular degeneration (AMD) is a progressive and degenerative disease affecting the posterior segment of the eye. It currently affects millions of people worldwide, and the gold standard of treatment has remained unchanged for over 20 years. It consists of intravitreal injections of anti-vascular endothelial growth factor (Anti-VEGF), which pose significant challenges to patient compliance primarily due to accessibility issues, fear of injections in the eye, and high cost. In this review, a thorough description of the pathogenesis of AMD and the anatomical barriers is presented that must be considered for the design of newer drug delivery systems for the treatment of AMD. Likewise, a critical evaluation of the most recent research efforts in the literature regarding the treatment of AMD using novel drug delivery technologies is provided. Lastly, currently approved therapeutic agents are reviewed for AMD and provide an insight into the recent surge of biosimilars with an outlook on how future therapeutic approaches to AMD should be developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.